Eli Lilly’s $3.25B acquisition of Kelonia Therapeutics caps startup’s tortuous ride
Eli Lilly is spending $3.25 billion to acquire Kelonia Therapeutics, a small biotech company developing cell therapies for…
FDA peptide advisers expected to support RFK Jr.’s legalization push
WASHINGTON — The Food and Drug Administration will convene an outside panel of advisers to discuss whether to…
Revolution Medicines touts success in pancreatic cancer treatment
Metastatic pancreatic cancer patients who received a targeted pill from Revolution Medicines lived nearly twice as long as…
Replimune skin cancer drug that became FDA flashpoint is rejected again
The Food and Drug Administration on Friday rejected — again — an experimental treatment for advanced skin cancer…
Trump administration readies tariffs for imported drugs
WASHINGTON — The Trump administration has prepared an order that would impose a 100% tariff on imports of…
J&J wins approval for first-of-its-kind psoriasis pill
Damian Garde is a reporter at large, live and feature journalism, covering the global drug industry and contributing…
BioNTech founders to leave, form new mRNA-focused company
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at…
Vertex says drug reduced marker of kidney disease in late-stage trial
Vertex said Monday that a drug it secured as part of a $4.9 billion acquisition successfully reduced by…
5 lessons from Vinay Prasad’s turbulent tenure at the FDA
Food and Drug Administration official Vinay Prasad self-destructed last week. The FDA announced Friday evening that he would…
FDA unveils new pathway for rare disease treatments
The Trump administration on Monday released detailed guidance for approving the first bespoke medicines crafted to treat patients’ individual…
Key study of Grail’s cancer detection test fails in setback for company
Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT…
FDA reverses course, agrees to review Moderna’s flu vaccine
WASHINGTON — The Food and Drug Administration reversed course and told Moderna it would review its application for…